OrphAI Therapeutics Announces Oral Presentation and Posters at the 22nd Annual NEALS Conference
GUILFORD, Conn., Oct. 02, 2023 (GLOBE NEWSWIRE) -- OrphAI Therapeutics Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today data presentations at the 22nd Annual NEALS (Northeast ALS Consortium) meeting being held October 4 - 6, 2023 in Clearwater Florida.
Oral Presentation:
October 5, 2023, 11:10 a.m. ET
-
Title: Results of the Phase 2a clinical trial of LAM-002A (apilimod dimesylate) in C9orf72 ALS
Presenters: Dr. Suma Babu, Sean M. Healey Center for ALS at MGHl; Peter Young, Ph.D. Chief Scientific Officer, OrphAI Therapeutics.
Location: Opal Ballroom
Poster Presentations:
-
Title: AIT-101 Improves Functional Deficits in a Human TDP-43 Animal Model of ALS
Presenter: Peter Young, Ph.D., Chief Scientific Officer, OrphAI Therapeutics
Location and Time: Poster Session 1, Abstract:4, October 4, 2023, 5:15p – 7:15p ET
-
Title: Results of a double blind, placebo-controlled clinical trial of AIT-101 (LAM-002A) in C9ORF72 ALS- A biomarker driven Phase 2a clinical trial targeting PIKfyve inhibition
Presenter: Dr. Suma Babu, Sean M. Healey Center for ALS at MGH
Location and Time: Poster Session 2, Abstract:136, October 5, 2023, 4:30p - 6:30p ET
About OrphAI Therapeutics
OrphAI Therapeutics’ mission is to transform the lives of patients with rare diseases. The company is currently developing three investigational therapies across multiple orphan indications: AIT-101, a first-in-class PIKfyve inhibitor, which recently completed a Phase 2a clinical trial in amyotrophic lateral sclerosis (ALS); LAM-001, a proprietary inhaled form of rapamycin, currently in Phase 2 for bronchiolitis obliterans syndrome (BOS) and pulmonary arterial hypertension (PAH); and AIT-102, a proprietary analogue of mithramycin, in preclinical development for the treatment of SWI/SNF mutated or dysregulated tumors. To learn more, please visit: OrphAI-Therapeutics.com
MEDIA CONTACT: info@orphai-therapeutics.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
